Scout Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Scout Investments’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-57,963	Closed	-$18.3M	–	223
2023 Q1	$18.3M	Sell	57,963 -32	-0.1%	-$9.6K	0.37%	98
2022 Q4	$16.7M	Sell	57,995 -56,701	-49%	-$17.3M	0.34%	95
2022 Q3	$33.2M	Sell	114,696 -155,620	-58%	-$44.8M	0.69%	55
2022 Q2	$76.2M	Sell	270,316 -217	-0.1%	-$58.1K	1.51%	9
2022 Q1	$70.6M	Buy	270,533 +11,775	+5%	+$2.79M	1.13%	20
2021 Q4	$56.8M	Buy	258,758 +12,385	+5%	+$2.41M	0.83%	31
2021 Q3	$44.7M	Buy	246,373 +82,519	+50%	+$16.1M	0.67%	39
2021 Q2	$33M	Buy	+163,854	New	+$34.3M	0.49%	70
2016 Q1	–	Sell	-24,460	Closed	-$3.08M	–	328
2015 Q4	$3.08M	Sell	24,460 -45,274	-65%	-$5.47M	0.08%	191
2015 Q3	$7.26M	Buy	69,734 +17,890	+35%	+$2.3M	0.17%	135
2015 Q2	$6.4M	Sell	51,844 -92,945	-64%	-$11.7M	0.12%	153
2015 Q1	$17.1M	Buy	+144,789	New	+$17.3M	0.28%	118
2013 Q4	–	Sell	-93,819	Closed	-$7.11M	–	299
2013 Q3	$7.11M	Sell	93,819 -73,775	-44%	-$5.87M	0.05%	192
2013 Q2	$13.4M	Buy	+167,594	New	+$12.3M	0.16%	129

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Scout Investments's VRTX Position: Q2 2023 in Review

Scout Investments sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 57,963 shares — an estimated $18.3M sold.

Scout Investments first reported a position in VRTX in Q2 2013 and held it in 14 quarters. The position peaked at $76.2M in Q2 2022. 1,286 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

Scout Investments reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Scout Investments sold 57,963 Vertex Pharmaceuticals shares in Q2 2023, an estimated $18.3M.
Scout Investments first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Scout Investments's Vertex Pharmaceuticals position peaked at $76.2M in Q2 2022.
1,286 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Scout Investments's 13F filing for Q2 2023, filed 14 Aug 2023.